Review
Classification and systemic glucocorticoids in the treatment of chronic rhinosinusitis
Sun Shujuan, Shi Guanggang
Published 2019-03-16
Cite as Int J Otolaryngol Head Neck Surg, 2019, 43(2): 84-89. DOI: 10.3760/cma.j.issn.1673-4106.2019.02.006
Abstract
Chronic Rhinosinusitis (CRS) is an inflammatory disease of the mucous membrane involving one or more sinuses, and also it is an important medical problem. CRS is classified as chronic rhinosinusitis with or without nasal polyps (CRSwNP or CRSsNP). The incidence of CRS in China is about 2.2%, which is lower than that in Europe and the United States (5% to 15%). CRSsNP shows Th1-type inflammation, and transforming growth factor-β (TGF-β) plays an important role in the pathogenesis of CRSsNP. Eosinophils, other inflammatory cells and Th2 inflammatory factors are participate in the disease of CRSwNP which performed Th2 inflammation.Nasal glucocorticoids are recommended for patients with CRSsNP and CRSwNP. Systemic glucocorticoids are recommended for CRSwNP, especially patients with severe or recurrent nasal polyps. Adults and children with CRSsNP are not recommended for systemic glucocorticoids.
Key words:
Sinusitis; Nasal Polyps; Glucocorticoids
Contributor Information
Sun Shujuan
Shandong Provincial ENT Hospital, Shandong Provincial ENT Hospital Affiliated to Shandong University, Jinan 250022, China
Shi Guanggang
Department of Otolaryngology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China